SciClone Pharmaceuticals (NASDAQ: SCLN) is a specialty pharmaceutical company with a substantial commercial business in China and a product portfolio spanning major therapeutic markets including oncology, infectious diseases and cardiovascular disorders. The company’s proprietary lead product, ZADAXIN^® (thymalfasin), is approved in over 30 countries and may be used for the treatment of hepatitis B (HBV), hepatitis C (HCV), and certain cancers, and as a vaccine adjuvant, according to local regulatory approvals. SciClone has successfully in-licensed and commercialized products, including DC Bead^®, a novel treatment for liver cancer. For more information, visit the company’s website at www.sciclone.com